Author

Firas Almazedi

Observed institution: Covance (United Kingdom)

OpenAlex ID: A5043625267

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

2021 · Wendy P. Painter, Wayne Holman, et al. · Antimicrobial Agents and Chemotherapy · 396

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes

2021 · Kirsten Dahl, Ashley Brooks, et al. · Diabetes Obesity and Metabolism · 91

Deferred registration: Fortrea code: 776181

2026 · Firas Almazedi · http://isrctn.com/

Phase 1 trial: Labcorp code 8501022

2023 · Firas Almazedi, Firas Almazedi, et al. · http://isrctn.com/

Author response for "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes"

2021 · Kirsten Dahl, Ashley Brooks, et al. · Publons reviews and discussion

Author response for "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes"

2021 · Kirsten Dahl, Ashley Brooks, et al. · Publons reviews and discussion

Author response for "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes"

2020 · Kirsten Dahl, Ashley Brooks, et al. · Publons reviews and discussion

Works count: 9

Citation count: 487

H-index: 2

I10-index: 2